140 related articles for article (PubMed ID: 26352490)
41. Prevalence of multiple sclerosis in Asahikawa, a city in northern Japan.
Itoh T; Aizawa H; Hashimoto K; Yoshida K; Kimura T; Katayama T; Koyama S; Yahara O; Kikuchi K
J Neurol Sci; 2003 Oct; 214(1-2):7-9. PubMed ID: 12972381
[TBL] [Abstract][Full Text] [Related]
42. Gender as a prognostic factor and its impact on the incidence of multiple sclerosis in Lorraine, France.
Debouverie M
J Neurol Sci; 2009 Nov; 286(1-2):14-7. PubMed ID: 19691994
[TBL] [Abstract][Full Text] [Related]
43. Limb apraxia in multiple sclerosis: prevalence and impact on manual dexterity and activities of daily living.
Kamm CP; Heldner MR; Vanbellingen T; Mattle HP; Müri R; Bohlhalter S
Arch Phys Med Rehabil; 2012 Jun; 93(6):1081-5. PubMed ID: 22464095
[TBL] [Abstract][Full Text] [Related]
44. Multiple sclerosis in Isfahan, Iran.
Saadatnia M; Etemadifar M; Maghzi AH
Int Rev Neurobiol; 2007; 79():357-75. PubMed ID: 17531850
[TBL] [Abstract][Full Text] [Related]
45. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
46. Multiple sclerosis in Iraq: does it have the same features encountered in Western countries?
Al-Araji A; Mohammed AI
J Neurol Sci; 2005 Jul; 234(1-2):67-71. PubMed ID: 15946690
[TBL] [Abstract][Full Text] [Related]
47. Clinical characteristics of multiple sclerosis in Lebanon.
Yamout B; Barada W; Tohme RA; Mehio-Sibai A; Khalifeh R; El-Hajj T
J Neurol Sci; 2008 Jul; 270(1-2):88-93. PubMed ID: 18367208
[TBL] [Abstract][Full Text] [Related]
48. Predictive value of clinical characteristics for 'benign' multiple sclerosis.
Ramsaransing GS; De Keyser J
Eur J Neurol; 2007 Aug; 14(8):885-9. PubMed ID: 17662009
[TBL] [Abstract][Full Text] [Related]
49. Steps per day among persons with multiple sclerosis: variation by demographic, clinical, and device characteristics.
Dlugonski D; Pilutti LA; Sandroff BM; Suh Y; Balantrapu S; Motl RW
Arch Phys Med Rehabil; 2013 Aug; 94(8):1534-9. PubMed ID: 23419331
[TBL] [Abstract][Full Text] [Related]
50. Quality of life in Polish patients with multiple sclerosis.
Mitosek-Szewczyk K; Kułakowska A; Bartosik-Psujek H; Hożejowski R; Drozdowski W; Stelmasiak Z
Adv Med Sci; 2014 Mar; 59(1):34-8. PubMed ID: 24797971
[TBL] [Abstract][Full Text] [Related]
51. Anorectal dysfunction in multiple sclerosis.
Munteis E; Andreu M; Téllez MJ; Mon D; Ois A; Roquer J
Mult Scler; 2006 Apr; 12(2):215-8. PubMed ID: 16629426
[TBL] [Abstract][Full Text] [Related]
52. High prevalence of restless legs syndrome in multiple sclerosis.
Manconi M; Fabbrini M; Bonanni E; Filippi M; Rocca M; Murri L; Ferini-Strambi L
Eur J Neurol; 2007 May; 14(5):534-9. PubMed ID: 17437613
[TBL] [Abstract][Full Text] [Related]
53. A clinical longitudinal study of multiple sclerosis in Cantabria, Spain.
Morís G; Berciano J; Miró J
Neurologia; 2003 Dec; 18(10):723-30. PubMed ID: 14648348
[TBL] [Abstract][Full Text] [Related]
54. [Dynamics of clinical presentations of multiple sclerosis in Amur region for the period of 1960 to 2005].
Karnaukh VN
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7 Suppl 2):75-8. PubMed ID: 19891350
[TBL] [Abstract][Full Text] [Related]
55. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
Ozakbas S; Ormeci B; Idiman E
J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
[TBL] [Abstract][Full Text] [Related]
56. [Pediatric multiple sclerosis: is it different from the adult form?].
Araqi-Houssaini A; Dany F; Sekkat Z; Camara NA; Hazim A; Midafi N; Elotmani H; El Moutawakil B; Rafai MA; Slassi I
Rev Neurol (Paris); 2014; 170(8-9):531-5. PubMed ID: 25174885
[TBL] [Abstract][Full Text] [Related]
57. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
58. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
[TBL] [Abstract][Full Text] [Related]
59. Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis.
D'hooghe MB; Haentjens P; Nagels G; De Keyser J
Eur J Neurol; 2012 Apr; 19(4):616-24. PubMed ID: 22117611
[TBL] [Abstract][Full Text] [Related]
60. Predictors of relapse rate in MS clinical trials.
Held U; Heigenhauser L; Shang C; Kappos L; Polman C;
Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
